A multivariate analysis showed that lung cancer patients with blood IGFBP2 > 160.9 ng/ml had a poor survival outcome (hazard ratio = 8.76, 95% CI 1.12-68.34, p=0.038 after adjustment for tumor size, pathology, and stage) (Table 2). The gene discussed is IGFBP2; the disease is lung carcinoma.